Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
BMM 3.80 +0.0% CGD 0.510 −10.5% OCG 0.275 −1.8% CAMB 0.990 −1.0% HMR 0.610 −1.6% GOFL 0.025 +0.0% SIG 1.02 −1.0% SGQ 0.300 +0.0% AMCO 0.220 −12.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.400 +0.0% LIB 0.790 −13.2% SMY 0.290 +23.4% SAG 1.02 +0.0% NTH 0.165 +0.0% BMM 3.80 +0.0% CGD 0.510 −10.5% OCG 0.275 −1.8% CAMB 0.990 −1.0% HMR 0.610 −1.6% GOFL 0.025 +0.0% SIG 1.02 −1.0% SGQ 0.300 +0.0% AMCO 0.220 −12.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.400 +0.0% LIB 0.790 −13.2% SMY 0.290 +23.4% SAG 1.02 +0.0% NTH 0.165 +0.0%
M&A / Property

Aurora Cannabis's MedReleaf adds Leafio as wholesaler

By The Northwire Desk — AI Analysis Dec 02, 2025 · 15:28 ACB · 6.37 Aurora Cannabis Inc
ACB · Price

Executive Summary

  • Aurora Cannabis Inc. (via its subsidiary MedReleaf Australia) has entered into a strategic distribution partnership with Leafio, the wholesale distribution arm of Montu Australia.
  • The agreement positions Leafio as the wholesaler for Aurora’s medical cannabis portfolio in Australia, significantly expanding patient access through Leafio’s nationwide supply chain.
  • The partnership leverages Leafio’s network of over 4,000 pharmacies and its focus on clinician education to support Aurora’s growth in the Australian medical cannabis market.

Key Details

  • Parties Involved: Aurora Cannabis Inc. (via wholly owned subsidiary MedReleaf Australia) and Leafio (wholesale distribution arm of Montu Australia).
  • Product Portfolio: Leafio will distribute Aurora’s leading medical cannabis products under the MedReleaf, CraftPlant, Aurora, Whistler Cannabis Co., and IndiMed brands.
  • Distribution Reach: Leafio’s nationwide supply chain services over 4,000 pharmacies across Australia.
  • Strategic Goals: Expand patient access to trusted, safe, and effective medical cannabis; support healthcare professionals with educational resources; and bolster Aurora’s leadership in the Australian market.
  • Product Certification: Aurora’s products are TGA-GMP-certified (Therapeutic Goods Administration good manufacturing practice).
  • Contact Information: Healthcare professionals and doctors can contact MedReleaf Australia's clinical support team or visit their website for further information.

Notable Quotes

  • Stanley Sack, Interim Managing Director of MedReleaf Australia: "We are excited to join forces with Leafio to improve access to consistent, high-quality medical cannabis for Australian patients. Our TGA-GMP-certified products, combined with Leafio's extensive sector knowledge and focus on clinician education, makes us ideal partners as we continue to grow our leadership in this important market."
  • Nicole Le Maistre, General Manager of Leafio: "Together, Leafio and Aurora can reach more Australian patients through trusted medical channels, bolstering access to world-class products and expertise. This partnership will deliver meaningful benefits to the region's medical cannabis industry, from enhanced research and product innovation to trusted education and improved patient outcomes."
Read the original news release →

More from Aurora Cannabis Inc

Jun 11, 2026 · 07:05

Record FY2026 revenue masks structural margin contraction and explicit FY2027 guide-cut; cash-rich but capital allocation remains dilutive.

Earnings May 14, 2026 · 08:45

Aurora Cannabis Secures IP Rights Amidst Sector Consolidation and Price Stabilization

M&A / Property May 14, 2026 · 06:54

Aurora Secures IP Moat Amidst Dilution Concerns and Cash Burn

M&A / Property Apr 28, 2026 · 15:57

Aurora Cannabis Expands Global Medical Portfolio Amidst Dilution Concerns and Profitability Push

Production / Operations Apr 28, 2026 · 06:53

Product Expansion Validates EU Capacity Play, But Dilution Risk Looms Over Cash Burn

Production / Operations Apr 15, 2026 · 07:05

Aurora Cannabis Acquires EU GMP Capacity Amidst Stock Decline

M&A / Property